Redcare Pharmacy NV (SAEYY)

OTCMKTS · Delayed Price · Currency is USD
4.000
-0.320 (-7.41%)
At close: Mar 23, 2026
Market Cap715.03M -76.6%
Revenue (ttm)3.45B +24.1%
Net Income-44.26M
EPS-2.20
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,250
Average Volume962
Open3.590
Previous Close4.320
Day's Range3.590 - 4.000
52-Week Range3.590 - 15.670
Beta1.07
RSI31.55
Earnings DateMar 4, 2026

About Redcare Pharmacy NV

Redcare Pharmacy NV operates the online pharmacy business in the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France. It offers prescription and non-prescription over-the-counter pharmaceuticals, beauty and personal care products, and food supplements. The company was formerly known as Shop Apotheke Europe N.V. and changed its name to Redcare Pharmacy NV in June 2023. Redcare Pharmacy NV was founded in 2001 and is based in Sevenum, the Netherlands. [Read more]

Sector Healthcare
Founded 2001
Employees 2,163
Stock Exchange OTCMKTS
Ticker Symbol SAEYY

Financial Performance

In 2025, Redcare Pharmacy NV's revenue was 2.94 billion, an increase of 24.06% compared to the previous year's 2.37 billion. Losses were -37.70 million, -17.14% less than in 2024.

Financial numbers in EUR Financial Statements

News

German online drug retailer Redcare Pharmacy names Hendrik Krampe as CFO

German online drug retailer Redcare Pharmacy on Monday named Hendrik Krampe as its chief financial officer, effective December 1.

4 months ago - Reuters

CTP Builds 30,000 sqm of Distribution Space for Redcare Pharmacy, Europe's Leading Online Pharmacy

AMSTERDAM--(BUSINESS WIRE)--Regulatory News: CTP, Europe's largest listed developer, owner, and manager of industrial and logistics properties by gross lettable area (GLA), today began the constructio...

1 year ago - Business Wire

Redcare Pharmacy aims for higher 2024 sales after positive annual core earnings

Redcare Pharmacy on Tuesday forecast higher sales for 2024 after the online pharmacy operator posted upbeat adjusted annual core earnings, supported by a growing number of prescription sales.

2 years ago - Reuters